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Abstract
Introduction: Healthcare-associated pneumonia (HCAP) is a relatively new category of pneumonia. It refers to
infections that occur prior to hospital admission in patients with specific risk factors following contact or exposure
to a healthcare environment. There is currently no scoring index to predict the outcomes of HCAP patients. We
applied and compared different community acquired pneumonia (CAP) scoring indices to predict 30-day mortality
and 3-day and 14-day intensive care unit (ICU) admission in patients with HCAP.
Methods: We conducted a retrospective cohort study based on an inpatient database from six medical centers,
recruiting a total of 444 patients with HCAP between 1 January 2007 and 31 December 2007. Pneumonia severity
scoring indices including PSI (pneumonia severity index), CURB 65 (confusion, urea, respiratory rate, blood pressure,
age 65), IDSA/ATS (Infectious Diseases Society of America/American Thoracic Society), modified ATS rule, SCAP
(severe community acquired pneumonia), SMART-COP (systolic blood pressure, multilobar involvement, albumin,
respiratory rate, tachycardia, confusion, oxygenation, pH), SMRT-CO (systolic blood pressure, multilobar involvement,
respiratory rate, tachycardia, confusion, oxygenation), and SOAR (systolic blood pressure, oxygenation, age,
respiratory rate) were calculated for each patient. Patient characteristics, co-morbidities, pneumonia pathogen
culture results, length of hospital stay (LOS), and length of ICU stay were also recorded.
Results: PSI (>90) has the highest sensitivity in predicting mortality, followed by CURB-65 (≥2) and SCAP (>9)
(SCAP score (area under the curve (AUC): 0.71), PSI (AUC: 0.70) and CURB-65 (AUC: 0.66)). Compared to PSI,
modified ATS, IDSA/ATS, SCAP, and SMART-COP were easy to calculate. For predicting ICU admission (Day 3 and
Day 14), modified ATS (AUC: 0.84, 0.82), SMART-COP (AUC: 0.84, 0.82), SCAP (AUC: 0.82, 0.80) and IDSA/ATS (AUC:
0.80, 0.79) performed better (statistically significant difference) than PSI, CURB-65, SOAR and SMRT-CO.
Conclusions: The utility of the scoring indices for risk assessment in patients with healthcare-associated
pneumonia shows that the scoring indices originally designed for CAP can be applied to HCAP.
Introduction
Healthcare-associated pneumonia (HCAP), a relatively
new category of pneumonia, refers to infections that
occur prior to hospital admission in patients with con-
tact or exposure to a healthcare environment [1]. Com-
pared to community-acquired pneumonia (CAP), HCAP
is a distinct type of pneumonia with unique microbiolo-
gical and epidemiological characteristics and outcomes
[2-6].
I nt h ec u r r e n te r ao fr i s i n gh e a l t h c a r ec o s t s ,t h ed e c i -
sion to hospitalize adults with CAP has received consid-
erable attention and many pneumonia severity
prediction rules have been designed to stratify patients
with CAP into risk groups [7,8]. Severity assessment is
n o to n l yt h ek e yt od e c i d i n gt h es i t eo fc a r eb u ta l s oi n
guiding both general management and antibiotic treat-
ment. Of the prominent tools for this purpose are the
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colleagues [9] and the CURB (confusion, urea, respira-
tory rate, blood pressure) score proposed by the British
Thoracic Society, and Infectious Diseases Society of
America/American Thoracic Society Consensus Guide-
lines on the Management of Community-Acquired
Pneumonia in Adults [10]. Other clinical prediction
rules for severe community-acquired pneumonia, like
the severe community acquired pneumonia (SCAP)
score were also developed, and were seemingly better at
identifying severe CAP. The SCAP is validated to predict
30-day mortality among two cohorts of consecutive
adult patients with CAP and identifies more patients as
low risk for potential outpatient care [11]. The need for
ICU care was better identified with the SOAR (systolic
blood pressure, oxygenation, age, respiratory rate) model
compared to the other scoring rules (CURB (confusion,
urea, respiratory rate, blood pressure), CURB-65 (confu-
sion, urea, respiratory rate, blood pressure, age 65),
CRB-65 (confusion, respiratory rate, blood pressure, age
65)) in patients with nursing home acquired pneumonia
[12], a subgroup of HCAP.
Each scoring system has its strengths and weaknesses.
As demonstrated by the studies on heterogeneous popu-
lations, validation studies of algorithms for HCAP ther-
apy will be difficult [13]. It would be very helpful if we
can apply the existing scoring systems to HCAP. How-
ever, to the best of our knowledge, none of these predic-
tion rules has been validated in patients hospitalized
with HCAP. Therefore, we sought to compare the per-
formance of the current scoring indices to predict mor-
tality and ICU admission in patients with HCAP.
Materials and methods
Setting and study design
This multi-center study was conducted at six medical
centers in Taiwan (Taipei Veterans General Hospital,
National Taiwan University Hospital, Taichung Veterans
General Hospital, China Medical University Hospital,
National Cheng Kung University Hospital, and Kaoh-
siung Chang Gung Memorial Hospital). All adult
patients presenting to one of the study hospitals with
pneumonia who were discharged between 1 January
2007 and 31 December 2007 were reviewed. According
to the 2005 IDSA/ATS (Infectious Diseases Society of
America/American Thoracic Society) guidelines [14], a
patient with HCAP is defined as one having pneumonia
and any of the following historical features: (1) hospitali-
zation for two or more days in an acute care facility
within 90 days of infection, (2) being a resident of a
nursing home or long-term care facility, (3) attending a
hospital or hemodialysis clinic, (4) having received intra-
venous antibiotic, chemotherapy, or wound care within
30 days of infection. The patients were excluded if they
had any one of the following conditions: (1) they were
younger than 18 years old; (2) their pneumonia devel-
oped two days after admission or within 14 days after
discharge; (3) they had lung cancer with obstructive
pneumonia; (4) they were HIV positive with a CD4+
<200; (5) there were inadequate data for scoring. A total
of 551 HCAP patients were recruited and 444 patients
with adequate data (with all variables for calculating all
scoring indices we compared available at admission)
were studied. The study was approved by the institu-
tional review board of each medical center and informed
consent was waived.
Microbiology evaluation
The specimens obtained within 72 h of admission were
eligible for etiologic evaluation, including sputum, tra-
cheal aspirate, bronchoalveolar lavage fluid, pleural effu-
sion, blood, and urine for Legionellae antigen test or
Streptococcus pneumoniae antigen test. The HCAP
pathogens were defined according to the principles pro-
posed by Lauderdale et al. [15].
In brief, etiology was determined based on laboratory
data from blood and sputum cultures plus serology
from paired serum and urine antigen detection tests.
Blood cultures were accepted if the same microorganism
was identified in a respiratory specimen and no other
source for the positive blood culture could be identified.
If the patients received bronchoscopic study, the definite
organisms were confirmed by quantitative bacterial cul-
tures BAL (bronchoalveolar lavage) >10
4/cfu or PSB
(protected sheath brushing) >10
3/cfu. The probable
pathogen was the organism isolated as a predominant
organism from sputum or endotracheal aspirate.
Definition of co-morbidities
The co-morbidities were defined according to the defini-
tion in the study by Fine et al. [9], including neoplastic
disease, liver disease, congestive heart failure, cerebro-
vascular disease, and renal disease.
Outcomes
The primary outcomes include 30-day all-cause mortal-
ity and ICU admission after 3 days and 14 days. The
lengths of both the ICU and hospital stay were also
determined.
Scoring indices
The modified ATS rule was met if at least two of three
minor criteria assessed at admission (systolic blood pres-
sure <90 mmHg, multilobar (>2 lobes) involvement,
PaO2/FiO2 <250), or one of two major criteria assessed
at admission or during follow-up (requirement for
mechanical ventilation or septic shock) were present
[16,17].
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America/American Thoracic Society Consensus Guide-
lines on the Management of Community-Acquired
Pneumonia in Adults [10]. In addition to the two major
criteria (need for mechanical ventilation and septic
shock), an expanded set of minor criteria (respiratory
rate ≥30 breaths/minute; arterial oxygen pressure/frac-
tion of inspired oxygen (PaO2/FiO2) ratio ≤250; multilo-
bar infiltrates; confusion; blood urea nitrogen level ≥20
mg/dL; leukopenia resulting from infection; thrombocy-
topenia; hypothermia; or hypotension requiring aggres-
sive fluid resuscitation) is proposed. The presence of at
least three of these criteria suggests the need for ICU
care.
SOAR comprises systolic blood pressure, oxygenation,
age, and respiratory rate [18]. We then defined severe
pneumonia as the presence of two or more out of the
four criteria. A score of 1 was given for the presence of
each of the following (dichotomized variables): systolic
BP <90 mmHg; PaO2:FiO2 <250; age ≥65 years; and RR
≥30/minute.
SCAP was proposed by Espana [19]. The evaluation of
SCAP is based on the presence of one major criterion
(PS) or two or more minor criteria (CURXO80). P =
arterial pH <7.3; S = systolic pressure <90 mmHg; C =
confusion; U = blood urea nitrogen >30 mg/dL; R =
respiratory rate >30/minute; X = X-ray multilobar bilat-
eral; O = PaO2 <54 or PaO2/FiO2 <250 mmHg; and 80
= Age ≥80 years.
SMART-COP (systolic blood pressure, multilobar
involvement, albumin respiratory rate, tachycardia, con-
fusion, oxygenation, pH) scores were calculated as pre-
sented by Charles [20], and consisted of systolic blood
pressure (<90 mmHg, two points); multilobar chest
radiography involvement (one point); low albumin level
(<3.5 g/dL, one point); high respiratory rate (≤50 years:
≥25 br/minute, >50 years: ≥30 br/minute; one point);
tachycardia (≥125 bpm; one point); confusion (new
onset; one point); poor oxygenation (≤50 years: PaO2
<70 mmHg or O2 saturation ≤93%, >50 years: PaO2 <60
mmHg or O2 saturation ≤9 0 % ;t w op o i n t s ) ;a n dl o w
arterial pH (<7.35; two points).
SMRT-CO (Simplified SMART-COP was designed for
use by primary care physicians, and it excludes the
results for albumin, arterial pH, and PaO2 [20]).
CURB-65 score is a six-point score, with one point
for each of: confusion; urea >7 mmol/l; respiratory rate
≥30/minute; low systolic (<90 mmHg) or diastolic (≤60
mmHg) blood pressure; and age ≥65 years [21].
The pneumonia severity index (PSI) was calculated as
presented in the study by Fine et al. [9], and is com-
prised of the following variables: age, gender, co-mor-
bidity, and vital sign abnormalities, together with several
laboratory, blood gas, and radiographic parameters. The
PSI results in a five-class point scoring system reflecting
the increasing risk of mortality.
Statistical analysis
Categorical variables were analyzed using a chi-square
test or Fisher’s exact test where appropriate, and contin-
uous variables were compared using Student’s t-test or
the Mann-Whitney U test. The discriminatory power of
each scoring index was measured by receiver operating
characteristic (ROC) curves. The areas under the ROC
curve (AUC) was calculated to give an estimate of the
overall accuracy of each scoring index in predicting dif-
ferent patient outcomes (3-day ICU admission, 14-day
ICU admission and 30-day mortality). An area of 0.50
implies that the scoring index is no better than chance,
whereas an area of 1 implies perfect accuracy. Sensitivity,
specificity, positive predictive value (PPV), and negative
predictive value (NPV) were also calculated as well with
their 95% confidence intervals for all the scoring indices.
The Hanley-McNeil test was used for testing the statisti-
cal significance of the difference between the two AUC
figures. All tests were two-tailed, and P-value <0.05 was
considered to be statistically significant. All statistical
analyses were performed using the SPSS 14.0 software
(SPSS Inc., Chicago, IL, USA) and the MedCalc 9.6.2.0
package (MedCalc Software, Mariakerke, Belgium).
Results
Enrolled background
A total of 444 patients met the inclusion criteria for
HCAP. Among these patients, there were 40 (9%)
patients receiving regular hemodialysis, peritoneal dialy-
sis, or infusion therapy. The enrolled patient back-
grounds are provided in Table 1. The all-cause mortality
rate at 30 days was 20.9%, and the 3-day ICU admission
and 14-day ICU admission rates were 25% and 29.1%,
respectively.
Patient demographics, clinical characteristics, and
bacterial pathogens
The demographic and clinical characteristics of the
patients with HCAP are provided in Tables 2 and 3.
There are no significant differences for gender and age
between survivors and non-survivors at 30 days post
admission. Patients who smoke have higher all-cause
mortality rates than non-smokers.
Neoplasm disease is the most important co-morbidity
which causes higher mortality. Other co-morbidities–
cerebrovascular disorders, renal disease, liver disease,
and diabetes mellitus–can predict a higher need for ICU
admission at Day 3.
Many of the predictors that were checked within two
days were associated with higher all-cause mortality and
the need for ICU admission. The predictors include a
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shock status, altered mental status, presence of pleural
effusion, pneumonia with multilobar involvement, high
fever or hypothermia, high BUN level, arterial blood
acidosis, and hypoxemia.
The pathogen yielded in patients who were admitted to
the ICU at 3 days and at 14 days tended to be Gram nega-
tive bacteria. Initial antibiotic choice is crucial and inade-
quate antibiotic administration could cause higher
mortality. Pseudomonas aeruginosa was the most frequently
found pathogen, followed by Klebsiella spp. (Table 4).
Scoring indices to predict mortality and ICU admission
hospital LOS
As shown in Table 5, the scoring indices originally
designed for CAP were tested to be applied to HCAP. The
adverse outcome rate increased steadily from low to high,
meeting the criteria for all scores. The average LOS
increased steadily from low to high, either for risk class or
meeting criteria. PSI can offer moderate discriminating
ability for separating patients between survivors and non-
survivors at 30 days, as well as for predicting the need for
ICU admission. The performance of each index in predict-
ing 3-day and 14-day ICU admission and 30-day mortality
were also determined (Tables 6 and 7). PSI (>90) has the
highest sensitivity to predicting mortality (AUC: 0.70), fol-
lowed by CURB-65 (≥2) (AUC: 0.66), and SCAP (>9)
( A U C :0 . 7 1 ) .F o rp r e d i c t i n gI C Ua d m i s s i o n( D a y3a n d
Day 14), modified ATS (AUC: 0.84, 0.82), SMART-COP
(AUC: 0.84, 0.82), SCAP (AUC: 0.82, 0.80) and IDSA/ATS
(AUC: 0.80, 0.79) performed better (statistically significant
difference) than PSI, CURB-65, SOAR and SMRT-CO.
Table 1 Background of patients with healthcare-associated pneumonia
3-day 14-day 30-day
All Non-ICU ICU Non-ICU ICU Survivors Non-Survivors
N = 444 N = 333 N = 111 N = 315 N = 129 N = 351 N =9 3
I.* Regular hemodialysis, peritoneal dialysis or
infusion therapy
40 (9.0) 27 (8.1) 13 (11.7) 26 (8.3) 14 (10.9) 38 (10.8) 2 (2.2)
II.
# Chemotherapy in out-patient clinics within
90 days
92 (20.7) 74 (22.2) 18 (16.2) 70 (22.2) 22 (17.1) 60 (17.1) 32 (34.4)
III.
† Hospitalization for ≥2 days within 90 days
before the onset of pneumonia
199 (44.8) 150 (45.0) 49 (44.1) 141 (44.8) 58 (45.0) 155 (44.2) 44 (47.3)
IV. Residents in a nursing home or long-term
care institute
113 (25.5) 82 (24.6) 31 (27.9) 78 (24.8) 35 (27.1) 98 (27.9) 15 (16.1)
P = 0.388 P = 0.558 P < 0.001
*The patients were classified into I if their enrolled background included I and the others (II, III or IV)
#The patients were classified into II if their enrolled background included II and III/IV
†The patients were classified into III if their enrolled background included III and IV
Table 2 Patient demographics characteristics (three-day ICU)
All N = 444 Non-ICU N = 333 ICU N = 111 P-value Survivors N = 351 Non-survivors N =9 3 P-value
Demographics
- Smoking 191 (43.0) 142 (42.6) 49 (44.1) 0.782 135 (38.5) 56 (60.2) <0.001
- Male 326 (73.6) 243 (73.2) 83 (74.8) 0.743 252 (72.0) 74 (79.6) 0.141
- Age, yrs 72.1 (15.1) 72 (15.6) 72.5 (13.6) 0.736 71.7 (15.3) 73.7 (14.1) 0.291
- Age ≥ 65 yrs 332 (74.8) 242 (72.7) 90 (81.1) 0.077 260 (74.1) 72 (77.4) 0.509
- Age ≥ 75 yrs 235 (52.9) 171 (51.4) 64 (57.7) 0.249 182 (51.9) 53 (57.0) 0.377
Comorbidity
- Charlson comorbidity score 2 (1 to 3) 2 (1 to 2) 2 (1 to 3) 0.013 2 (1 to 2) 2 (2 to 3) <0.001
- Neoplastic disease 166 (37.4) 131 (39.3) 35 (31.5) 0.141 108 (30.8) 58 (62.4) <0.001
- Liver disease 28 (6.3) 16 (4.8) 12 (10.8) 0.024 21 (6.0) 7 (7.5) 0.586
- Cardiovascular disease 68 (15.3) 43 (12.9) 25 (22.5) 0.015 52 (14.8) 16 (17.2) 0.569
- Cerebrovascular disorders 120 (27.0) 81 (24.3) 39 (35.1) 0.026 100 (28.5) 20 (21.5) 0.177
- CNS 67 (15.1) 56 (16.8) 11 (9.9) 0.078 57 (16.2) 10 (10.8) 0.189
- Renal disease 81 (18.2) 51 (15.3) 30 (27.0) 0.006 67 (19.1) 14 (15.1) 0.370
- Pulmonary disease 114 (25.7) 82 (24.6) 32 (28.8) 0.380 88 (25.1) 26 (28.0) 0.571
- Diabetes mellitus 130 (29.3) 89 (26.7) 41 (36.9) 0.041 103 (29.3) 27 (29.0) 0.953
- Immunocompromised status 54 (12.2) 38 (11.4) 16 (14.4) 0.402 43 (12.3) 11 (11.8) 0.912
*Data are expressed as number count (percentage) or median (interquartile range)
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All N = 444 Non-ICU N = 333 ICU N = 111 P-
value
Survivors N = 351 Non-survivors N =9 3 P-
value
Clinical features
- Received ventilation 139 (31.3) 45 (13.5) 94 (84.7) <0.001 87 (24.8) 52 (55.9) <0.001
- Septic shock 104 (23.4) 49 (14.7) 55 (49.5) <0.001 61 (17.4) 43 (46.2) <0.001
- Altered mental status 111 (25.0) 53 (15.9) 58 (52.3) <0.001 66 (18.8) 45 (48.4) <0.001
- Pleural effusion 144 (32.4) 97 (29.1) 47 (42.3) 0.010 101 (28.8) 43 (46.2) 0.001
- Multilobar involvement 242 (54.5) 161 (48.3) 81 (73.0) <0.001 174 (49.6) 68 (73.1) <0.001
- Temperature <35°C or ≥40°C 8 (1.8) 3 (0.9) 5 (4.5) 0.026 3 (0.9) 5 (5.4) 0.012
- BUN >20 mg/dL 279 (62.8) 191 (57.4) 88 (79.3) <0.001 206 (58.7) 73 (78.5) <0.001
- BUN >30 mg/dL 164 (36.9) 107 (32.1) 57 (51.4) <0.001 113 (32.2) 51 (54.8) <0.001
- Pulse ≥125/minute 97 (21.8) 63 (18.9) 34 (30.6) 0.010 81 (23.1) 16 (17.2) 0.223
- Respiratory rate >30/minute 31 (7.0) 14 (4.2) 17 (15.3) <0.001 24 (6.8) 7 (7.5) 0.817
- Systolic BP <90 mmHg 35 (7.9) 18 (5.4) 17 (15.3) 0.001 21 (6.0) 14 (15.1) 0.004
- Distolic BP ≤60 mmHg 121 (27.3) 84 (25.2) 37 (33.3) 0.097 87 (24.8) 34 (36.6) 0.023
- Haematocrit <30% 144 (32.4) 110 (33.0) 34 (30.6) 0.640 105 (29.9) 39 (41.9) 0.028
- Arterial PH <7.35 65 (14.6) 23 (6.9) 44 (39.6) <0.001 41 (11.7) 24 (25.8) 0.001
- Glucose ≥250 mg/dL 44 (9.9) 28 (8.4) 16 (14.4) 0.067 34 (9.7) 10 (10.8) 0.760
- PaO2 <60 mmHg 86 (19.4) 49 (14.7) 37 (33.3) <0.001 59 (16.8) 27 (29.0) 0.005
Initial antibiotic therapy§ 0.583 0.001
- Inadequate 75 (16.9) 57 (17.1) 18 (16.2) 52 (14.8) 23 (24.7)
- Adequate 158 (35.6) 162 (48.6) 49 (44.1) 117 (33.3) 41 (44.1)
- Indeterminate 211 (47.5) 114 (34.2) 44 (39.6) 182 (51.9) 29 (31.2)
Outcome
- Length of ICU stay, days 8 (4 to 17) ———— 8 (4 to 17) — 12 (6.5 to 8.5) 8 (2 to 15.3) 0.002
- Length of hospital stay, days 15 (9 to 25) 15 (8 to 23) 19 (9 to 37) 0.038 17 (9 to 29) 9 (4 to 20) <0.001
- In-hospital mortality 117 (26.4) 64 (19.2) 53 (47.8) <0.001 24 (6.9) 93 (100.0) <0.001
*Data are expressed as number count (percentage) or median (interquartile range)
§Inadequate initial antibiotic therapy was defined as the condition when the therapy was unable to cover any of the isolated bacterium
Table 4 Etiology of healthcare-associated pneumonia
All 3-day ICU Admission 14-day ICU Admission 30-day Mortality
N = 259* N =8 4 † N = 91¶ N = 58§
Gram-negative pathogens
- Pseudomonas spp. 83 (32.0) 25 (29.8) 26 (28.6) 19 (32.8)
- Klebsiella spp. 72 (27.8) 23 (27.4) 23 (25.3) 13 (22.4)
- Acinetobater spp. 8 (3.1) 2 (2.4) 3 (3.3) 4 (6.9)
- Escherichia coli 14 (5.4) 4 (4.8) 6 (6.6) 3 (5.2)
- Enterbacterium spp. 14 (5.4) 6 (7.1) 7 (7.7) 4 (6.9)
- Haemophilus influenzae 6 (2.3) 4 (4.8) 4 (4.4)
- Proteus mirabilis 6 (2.3) 1 (1.2) 2 (2.2) 1 (1.7)
- Serratia marcescens 6 (2.3) 2 (2.4) 2 (2.2) 2 (3.4)
- Stenotrophmonas maltophilia 5 (1.9) 2 (2.4) 2 (2.2) 1 (1.7)
- Other 1 (0.3)
Gram-positive pathogens
- Streptococcus pneumoniae 8 (3.1) 5 (6.0) 5 (5.5) 1 (1.7)
- MRSA 22 (8.5) 5 (6.0) 6 (6.6) 7 (12.1)
- MSSA 8 (3.1) 3 (3.6) 3 (3.3) 3 (5.2)
- Other Streptococcus spp. 4 (1.5) 2 (2.4) 2 (2.2)
- Other 1 (0.3)
Other 1 (0.3)
*From 204 subjects. †From 66 subjects. ¶From 72 subjects. §From 45 subjects.
MRSA: methicillin-resistant Staphylococcus aureus
MSSA: methicillin-sensitive Staphylococcus aureus
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HCAP is a heterogeneous disease that includes patient
populations with varying severities of illness [22]. The
mortality associated with HCAP was similar to that of
nosocomial pneumonia, higher than that of CAP, and
lower than ventilator-associated pneumonia [13]. As
shown in Table 1, each subgroup contributes to differ-
ent parts of overall HCAP mortality. There is increased
mortality of groups II (34.4%) and III (47.3%) of patients
with HCAP, indicating that HCAP is a heterogeneous
disease. As has already been reported by Brito and Nie-
derman, all patients with HCAP should be identified
and then divided on the basis of severity of illness to
guide initial therapy [13]. Severe pneumonia has been
defined by the requirement for admission to an ICU
[16]. The decision to admit a patient with HCAP to an
ICU depends on subjective clinical views and the pecu-
liarities of the local healthcare setting. The availability of
valid criteria for defining severe pneumonia would pro-
v i d eam o r er e l i a b l eb a s i sf o ri m p r o v i n gp a t i e n tr i s k
Table 5 ICU admission, mortality, and hospital LOS according to different prediction rules
Patients 3-day ICU Admission 14-day ICU Admission 30-day Mortality Hospital LOS, d*
Total number of patients 444 111 129 93
Modified ATS
- Low (not meeting criteria) 248 (55.9) 6 (2.4) 13 (5.2) 25 (10.1) 14 (8.3 to 22.8)
- High (meeting criteria) 196 (44.1) 105 (53.6) 116 (59.2) 68 (34.7) 18 (9 to 29.8)
P-value <0.001 <0.001 <0.001 0.013
IDSA/ATS
- Low (not meeting criteria) 234 (52.7) 8 (3.4) 15 (6.4) 22 (9.4) 14 (8.8 to 23)
- High (meeting criteria) 210 (47.3) 103 (49.0) 114 (54.3) 71 (33.8) 17 (9 to 29)
P-value <0.001 <0.001 <0.001 0.058
SOAR
- Low (not meeting criteria) 317 (71.4) 42 (13.2) 56 (17.7) 54 (17.0) 15 (8 to 23)
- High (meeting criteria) 127 (28.6) 69 (54.3) 73 (57.5) 39 (30.7) 17 (9 to 34)
P-value <0.001 <0.001 0.001 0.018
SCAP
- Low (0 to approximately 9) 184 (41.4) 12 (6.5) 17 (9.2) 18 (9.8) 14 (8 to 23)
- Intermediated (10 to approximately 19) 164 (36.9) 41 (25.0) 50 (30.5) 33 (20.1) 16 (9 to 25)
- High (≥20) 96 (21.6) 58 (60.4) 62 (64.6) 42 (43.8) 18 (9 to 34.8)
P-value <0.001 <0.001 <0.001 0.049
SMART-COP
- Low (0 to approximately 2) 275 (61.9) 21 (7.6) 31 (11.3) 35 (12.7) 14 (9 to 23)
- Intermediate (3 to approximately 4) 93 (20.9) 39 (41.9) 43 (46.2) 28 (30.1) 17 (8 to 27)
- High (≥5) 76 (17.1) 51 (67.1) 55 (72.4) 30 (39.5) 17.5 (9 to 32)
P-value <0.001 <0.001 <0.001 0.138
SMRT-CO
- Low (0 to approximately 1) 291 (65.5) 41 (14.1) 51 (17.5) 44 (15.1) 15 (9 to 23)
- Intermediate (2) 83 (18.7) 25 (30.1) 31 (37.3) 22 (26.5) 18 (8 to 29)
- High (≥3) 70 (15.8) 45 (64.3) 47 (67.1) 27 (38.6) 17 (7.8 to 27)
P-value <0.001 <0.001 <0.001 0.431
CURB65
- Low (0 to approximately 1) 142 (32.0) 12 (8.5) 16 (11.3) 12 (8.5) 14 (8 to 23)
- Intermediate (2) 153 (34.5) 33 (21.6) 42 (27.5) 34 (22.2) 15 (9 to 23.5)
- High (≥3) 149 (33.6) 66 (44.3) 71 (47.7) 47 (31.5) 17 (8 to 29)
P-value <0.001 <0.001 <0.001 0.166
PSI
- Low (≤90, Class I to approximately III) 80 (18.0) 8 (10.0) 10 (12.5) 7 (8.8) 12 (7.3 to 20.8)
- Intermediate (91 to 130, Class IV) 205 (46.2) 36 (17.6) 46 (22.4) 33 (16.1) 16 (9 to 24)
- High (>130, Class V) 159 (35.8) 67 (42.1) 73 (45.9) 53 (33.3) 17 (8 to 29)
P-value <0.001 <0.001 <0.001 0.028
*Data are presented as median (interquartile range). Non-parametric Mann-Whitney U test or Jonckheere-Terpstra’s trend test was used to examine the
statistically significant differences between groups.
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Page 6 of 10Table 6 Measure of performance predicting 3-day and 14-day ICU admission and 30-day mortality by using different
prediction rules
Sensitivity Specificity PPV NPV AUC
Modified ATS
- ICU admission (3 d) 94.6 (88.6 to 98.0) 72.7 (67.5 to 77.4) 53.6 (46.3 to 60.7) 97.6 (94.8 to 99.1) 0.836 (0.799 to 0.870)
- ICU admission (14 d) 89.9 (83.4 to 94.5) 74.6 (69.4 to 79.3) 59.2 (52.0 to 66.1) 94.8 (91.2 to 97.2) 0.823 (0.784 to 0.857)
- Mortality 73.1 (62.9 to 81.8) 63.5 (58.3 to 68.6) 34.7 (28.1 to 41.8) 89.9 (85.5 to 93.4) 0.683 (0.638 to 0.726)
IDSA/ATS
- ICU admission (3 d) 92.8 (86.3 to 96.8) 67.9 (62.6 to 72.9) 49.0 (42.1 to 56.0) 96.6 (93.4 to 98.5) 0.803 (0.763 to 0.839)
- ICU admission (14 d) 88.4 (81.5 to 93.3) 69.5 (64.1 to 74.6) 54.3 (47.3 to 61.2) 93.6 (89.6 to 96.4) 0.789 (0.749 to 0.826)
- Mortality 76.3 (66.4 to 84.5) 60.4 (55.1 to 65.6) 33.8 (27.4 to 40.6) 90.6 (86.1 to 94.0) 0.684 (0.638 to 0.727)
SOAR
- ICU admission (3 d) 62.2 (52.5 to 71.2) 82.6 (78.1 to 86.5) 54.3 (45.3 to 63.2) 86.8 (82.5 to 90.3) 0.724 (0.680 to 0.765)
- ICU admission (14 d) 56.6 (47.6 to 65.3) 82.9 (78.2 to 86.9) 57.5 (48.4 to 66.2) 82.3 (77.7 to 86.4) 0.697 (0.652 to 0.740)
- Mortality 41.9 (31.8 to 52.6) 74.9 (70.1 to 79.4) 30.7 (22.8 to 39.5) 83.0 (78.4 to 86.9) 0.584 (0.537 to 0.631)
SCAP (>9)
- ICU admission (3 d) 89.2 (81.9 to 94.3) 51.7 (46.1 to 57.1) 38.1 (32.1 to 44.3) 93.5 (88.9 to 96.6) 0.818 (0.778 to 0.852)
- ICU admission (14 d) 86.8 (79.7 to 92.1) 53.0 (47.3 to 58.6) 43.1 (37.0 to 49.3) 90.8 (85.6 to 94.5) 0.801 (0.760 to 0.837)
- Mortality 80.7 (71.1 to 88.1) 47.3 (42.0 to 52.7) 28.8 (23.4 to 34.8) 90.2 (85.0 to 94.1) 0.709 (0.664 to 0.751)
SMART-COP (>2)
- ICU admission (3 d) 81.1 (72.5 to 87.9) 76.3 (71.3 to 80.7) 53.3 (45.4 to 61.0) 92.4 (88.6 to 95.2) 0.836 (0.798 to 0.869)
- ICU admission (14 d) 76.0 (67.7 to 83.0) 77.5 (72.4 to 82.0) 58.0 (50.2 to 65.5) 88.7 (84.4 to 92.2) 0.822 (0.783 to 0.857)
- Mortality 62.4 (51.7 to 72.2) 68.4 (63.2 to 73.2) 34.3 (27.2 to 42.0) 87.3 (82.7 to 91.0) 0.686 (0.641 to 0.729)
SMRT-CO (>1)
- ICU admission (3 d) 63.1 (53.4 to 72.0) 75.1 (70.1 to 79.6) 45.8 (37.7 to 54.0) 85.9 (81.4 to 89.7) 0.756 (0.713 to 0.795)
- ICU admission (14 d) 60.5 (51.5 to 69.0) 76.2 (71.1 to 80.8) 51.0 (42.8 to 59.1) 82.5 (77.6 to 86.7) 0.751 (0.708 to 0.791)
- Mortality 52.7 (42.1 to 63.1) 70.4 (65.3 to 75.1) 32.0 (24.7 to 40.0) 84.9 (80.2 to 88.8) 0.672 (0.627 to 0.716)
CURB-65 (>1)
- ICU admission (3 d) 89.2 (81.9 to 94.3) 39.0 (33.8 to 44.5) 32.8 (27.5 to 38.4) 91.5 (85.7 to 95.6) 0.732 (0.688 to 0.772)
- ICU admission (14 d) 87.6 (80.6 to 92.7) 40.0 (34.5 to 45.6) 37.4 (31.9 to 43.1) 88.7 (82.3 to 93.4) 0.715 (0.670 to 0.756)
- Mortality 87.1 (78.5 to 93.1) 37.0 (32.0 to 42.3) 26.8 (21.9 to 32.2) 91.5 (85.7 to 95.6) 0.662 (0.616 to 0.706)
PSI (>90)
- ICU admission (3 d) 92.8 (86.3 to 96.8) 21.6 (17.3 to 26.4) 28.3 (23.7 to 33.2) 90.0 (81.2 to 95.6) 0.730 (0.868 to 0.771)
- ICU admission (14 d) 92.3 (86.2 to 96.2) 22.2 (17.8 to 27.2) 32.7 (27.9 to 37.8) 87.5 (78.2 to 93.8) 0.717 (0.673 to 0.759)
- Mortality 92.5 (85.1 to 96.9) 20.8 (16.7 to 25.4) 23.6 (19.4 to 28.3) 91.3 (82.8 to 96.4) 0.703 (0.658 to 0.745)
Data are presented as percentages (95% confidence interval)
The scores were dichotomized as low risk vs. higher risk (Modified ATS: meeting criteria, IDSA/ATS: meeting criteria, SOAR: meeting criteria, SCAP >9, SMART-COP
>2, SMRT-CO >1, CURB-65 >1, PSI >90).
Table 7 Pairwise comparison of ROC curves (the number represents the p-value)
Modified ATS IDSA/ATS SOAR SCAP SMART-COP SMRT-CO CURB-65 PSI
Modified ATS 0.984 †, 0.006 0.443 0.934 0.769 0.588 0.623
IDSA/ATS 0.070/0.066 †, 0.008 0.458 0.948 0.750 0.561 0.627
SOAR #, 0.001/<0.001 #, 0.024/0.005 †,< 0.001 †, 0.001 †, 0.013 †, 0.028 †, 0.002
SCAP 0.532/0.436 0.640/0.697 #, 0.001/<0.001 0.309 0.215 0.152 0.836
SMART-COP 0.996/0.985 0.286/0.259 #, <0.001/<0.001 0.358/0.259 0.555 0.526 0.647
SMRT-CO #, 0.015/0.020 0.146/0.209 0.339/0.086 #, 0.020/0.049 #, <0.001/<0.001 0.777 0.456
CURB-65 #, 0.003/0.001 #, 0.034/0.018 0.807/0.577 #, 0.003/0.001 #, 0.001/<0.001 0.461/0.240 0.223
PSI #, 0.003/0.001 #, 0.037/0.028 0.854/0.548 #, 0.001/0.001 #, 0.001/<0.001 0.477/0.316 0.960/0.930
*The cells in bold and italics represent the p-value in pairwise comparison for predicting the 30-day mortality, the normal cells represent the P-value for
predicting the ICU-admission (3-day/14-day)
† Statistically significant difference in predicting 30-day mortality
# Statistically significant difference in predicting both 3-day and 14-day ICU admission.
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Page 7 of 10assessments. The severity on admission can affect hospi-
tal mortality, the need for ICU admission, and even 90-
day mortality after hospital discharge [23]. A number of
prognostic scoring tools have been developed to predict
mortality and the need for ICU care for patients with
CAP; the two tools that have been studied the most are
the PSI and CURB-65. However, they are not ideal for
assessing the need for ICU care, and other scoring sys-
tems, such as those developed by the IDSA/ATS guide-
line group, and the SMART-COP tool, are available for
this purpose [24]. So far, and to the best of our knowl-
edge, no severity index has been developed and vali-
dated for patients with HCAP.
T h eA U Ci sam e a s u r eo ft h ea c c u r a c yo fat e s tt o
correctly classify patients with and without a particular
outcome and is used frequently in studies of severity
assessment in CAP. The AUC describes the relation-
ships between sensitivity and specificity, a higher AUC
implies a less steep trade-off between sensitivity and
specificity. An AUC is considered to have moderate dis-
criminating power from a value of 0.70 on up. We con-
ducted this retrospective chart review of 444 records
and assessed the validity of PSI, CURB-65, SCAP, and
others and constructed an ROC.
The PSI scoring system has been shown to be a power-
ful tool for assigning the risk of death from CAP in dif-
ferent populations [17]. This scoring system was
primarily designed to identify patients with a low mortal-
ity risk who could safely be treated as outpatients. How-
ever, it is complicated to use, requiring computation of a
score based on 20 variables. To ensure that the final pre-
diction rule remained simple to use and practical, prog-
nostic features not usually available at the time of initial
assessment post hospital admission were excluded from
the CURB-65 model [21]. The CURB-65 model does not
consider decompensated co-morbidity due to CAP and
results in limited application in the elderly [24]. Since the
majority of patients were elderly, the data are not much
different from what is published in the literature regard-
ing CAP; that is, CURB-65 may not be a good index for
predicting mortality in this population.
The modified ATS rule provides simple clinical cri-
teria for those patients who require ICU admission [16].
According to the authors’ description, the modified ATS
rule can serve as a useful counterpart to the prediction
by Fine et al. The modified ATS rule was good in terms
of sensitivity (89.9%) and the area under the receiver
operator curve graph (0.823) for predicting 14-day ICU
admission in HCAP patients. The modified ATS severe
CAP definition published in 2001 was superseded by the
2007 IDSA-ATS severe CAP definition (IDSA/ATS).
The newer definition was based on a series of papers
and on re-evaluation by the guideline committee of data
published since the 2001 definition was made.
Therefore, we also tested the two indices and found that
modified ATS as well as IDSA/ATS can be applied for
defining severe HCAP.
The strongest clinical predictors of SCAP were pH
<7.30 and systolic pressure <90 mmHg [19]. A
depressed pH, which is likely a side effect of metabolic
acidosis derived from sepsis, is not included in other
prediction rules, such as CURB-65 or modified ATS. In
our series, a low pH was associated with poor outcomes
in patients with HCAP. The SCAP score is as accurate
a s ,o rb e t t e rt h a n ,o t h e rc u r r e n ts c o r i n gs y s t e m s( f o r
example, CURB-65 and PSI) in predicting adverse out-
comes in patients hospitalized with CAP [25]. We found
that SCAP also works well with HCAP. The discrimina-
tory power of SCAP, as measured by AUC, was 0.81 for
ICU admission in our HCAP patients, compared with
the 0.75 in CAP patients from another study [25].
The PSI and CURB-65 have been used to guide the
need for ICU care, but they are not ideal for this pur-
pose [24]. Some of these indices were originally
designed to assess ICU admission rather than mortality.
Therefore, a poor performance could be found if applied
in predicting mortality. Compared to PSI, modified ATS,
IDSA/ATS, SCAP, and SMART-COP were easy to cal-
culate. For predicting ICU admission (Day 3 and Day
14), modified ATS (AUC: 0.84, 0.82), SMART-COP
(AUC: 0.84, 0.82), SCAP (AUC: 0.82, 0.80) and IDSA/
ATS (AUC: 0.80, 0.79) performed better (showing a sta-
tistically significant difference) than PSI, CURB-65,
SOAR and SMRT-CO.
The main strength of the study is the relatively large
sample size. The limitations of the study include possible
selection bias as all patients who were included in our ana-
lysis consist of a heterogenic variety of sources. There may
be different patient characteristics in each study site. On
the other hand, it can reflect the reality of HCAP coming
from heterogeneous populations. In addition, there are a
huge number of patients that received microbiologically
adequate therapy (sensitive to the antibiotic administered)
and their clinical conditions do not improve because of
other possible factors (for example, incorrect dosing, inter-
val of administration, pharmacokinetic/pharmacodynamic
features, hypoalbuminemia in critically ill patients) which
were not investigated in this study. However, those were
beyond the scope of the study.
Conclusions
The utility of the scoring indices for risk assessment in
patients with healthcare-associated pneumonia shows
that the scoring indices originally designed for CAP can
be applied to HCAP. The promising results offer the clin-
ician an adjunctive tool when making site-of-treatment
decisions for patients and when stratifying patients with
HCAP into risk groups.
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￿ There is currently no scoring index to predict the
outcomes of patients with HCAP, a type of pneumo-
nia that occurs prior to hospital admission in
patients with specific risk factors following contact
or exposure to a healthcare environment.
￿ We applied and compared different community
acquired pneumonia (CAP) scoring indices to pre-
dict 30-day mortality and 3-day and 14-day intensive
care unit (ICU) admission in patients with HCAP.
￿ PSI has the highest sensitivity in predicting mortal-
ity, followed by CURB-65 (≥2) and SCAP (>9)
(SCAP score (AUC: 0.71), PSI (AUC: 0.70) and
CURB-65 (AUC: 0.66)).
￿ For predicting ICU admission (Day 3 and Day 14),
modified ATS (AUC: 0.84, 0.82), SMART-COP
(AUC: 0.84, 0.82), SCAP (AUC: 0.82, 0.80) and
IDSA/ATS (AUC: 0.80, 0.79) performed better (sta-
tistically significant difference) than PSI, CURB-65,
SOAR and SMRT-CO.
￿ The promising results offer the clinician an adjunc-
tive tool when making site-of-treatment decisions for
patients and when stratifying patients with HCAP
into risk groups.
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